Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 10, 2001, Pages 4874-4880

  Luzio, Stephen D ^a   Anderson, Denise M ^b   Owens, David R ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b Ajinomoto Pharmaceut Europe Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NATEGLINIDE; ORAL ANTIDIABETIC AGENT;

ARTICLE; CARBOHYDRATE DIET; CHRONOPHARMACOLOGY; CLINICAL TRIAL; DRUG BLOOD LEVEL; FOOD COMPOSITION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID DIET; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DIET;

EID: 0034750681     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.10.7911     Document Type: Article

References (27)

1. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: A balanced overview
2. Type 2 (non-insulin-dependent) diabetes mellitus: The thrifty phenotype hypothesis
3. Insulin action, diabetogenes, and the cause of type II diabetes
4. A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes meltitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis
5. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK
6. Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects
7. 2+ influx
8. A new hypoglycaemic agent A-4166 inhibits ATP-sensitive potassium channels in rat pancreatic B-cells
9. Somatostatin and insulin secretion due to common mechanisms by a new hypoglycaemic agent A-4166 in perfused rat pancreas
10. Ay-4166 increases the sensitivity of insulin secretion to glucose in isolated perfused rat pancreas
11. Studies on the N[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) receptor in HIT T-15 cells
12. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166
13. New non-sulfonylurea insulin secretagogues
14. Stimulating activity of A-4166 on insulin release in in situ hamster pancreatic perfusion
15. Synergistic effects of nateglinide and meal adrninistration on insulin secretion in patients with type 2 diabetes mellitus
16. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes
17. Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus
18. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients
19. Mimicking cephalic insulin release with the rapid onset/short duration insulinotrophic agent, nateglinide, reduces prandial glucose excursions without increasing total insulin exposure in IGT monkeys
20. Insulin deficiency in non-insulin-dependent diabetes
21. Pancreatic beta-cell responsiveness during meal tolerance test: Model assessment in normal subjects and subjects with newly diagnosed non-insulin-dependent diabetes mellitus
22. Glucose tolerance and coronary heart disease: Helsinki Policemen Study
23. High blood glucose concentration is a risk factor for mortality, in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study
24. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications
25. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
26. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonyinreas
27. Repaglinide prandial glucose regulator: A new class of oral antidiabetic drugs